This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA Mandates New Boxed Warning for Fluoroquinolones
Revised Label to Highlight Risk of Tendonitis, Tendon Rupture
By News Staff
"Fluoroquinolones are in common use for older patients for urinary tract infections and for COPD (chronic obstructive pulmonary disease) exacerbations," said Jonathan Temte, M.D., Ph.D., of Madison, Wis. An associate professor at the University of Wisconsin School of Medicine and Public Health in Madison, Temte is an infectious disease researcher and a member of the CDC's Advisory Committee on Immunization Practices.
"Whereas their use may not be first-line, they are used extensively in the primary care arena," he added.
In an FDA alert sent to health care professionals, agency officials noted that the risk of these tendon problems is even greater in people who are older than 60, patients who are taking steroids, and those who have had a lung, kidney or heart transplant.
"Health care professionals should consider the potential benefit and risks to each individual patient before prescribing a fluoroquinolone antimicrobial," the FDA alert noted. "While most patients prescribed fluoroquinolones tolerate these medicines, rarely, patients develop serious adverse reactions, which may include convulsions, hallucinations, depression, QTc prolongation and torsades de pointes, or Clostridium difficile-associated diarrhea.
"Rarely, damage to the liver, kidneys or bone marrow, or alterations in glucose homeostasis may occur."
According to the FDA, patients taking fluoroquinolones should be advised to discontinue the drug right away if they experience pain or inflammation in a tendon area. They also should avoid exercise and use of the affected area and consult their physician promptly about possibly switching to a non-fluoroquinolone antimicrobial.
Medications included in this class of drugs are ciprofloxacin, marketed as Cipro and generic ciprofloxacin; ciprofloxacin extended release, marketed as Cipro XR and Proquin XR; gemifloxacin, marketed as Factive; levofloxacin, marketed as Levaquin; moxifloxacin, marketed as Avelox; norfloxacin, marketed as Noroxin; and ofloxacin, marketed as Floxin and generic ofloxacin.
The FDA action applies only to systemic fluoroquinolones; topical formulations, such as ophthalmic or otic drops, are not affected.
Physicians can contact MedWatch, the FDA's Safety Information and Adverse Event Reporting Program, to report any serious adverse events associated with the use of fluoroquinolones or other drugs, dietary supplements, biologic agents or medical devices.
Antibiotic Resistance Grows
CDC: Don't Use Fluoroquinolones for Gonococcal Infections
(4/20/2007)
Additional Resources
Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs
MedWatch
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Study: PPI Does Not Routinely Improve Asthma Control
Recalled Oral Contraceptives Pose Pregnancy Risk
CDC to Fund 2D Vaccine Barcoding Pilot
2012 Immunization Schedules Reflect Multiple Changes
Study: Cognitive Decline Detected in Middle-aged Adults
CDC Toolkit Can Help Clinicians Fight Norovirus Infection
Patient-Centered Care Linked to Lower Mortality
Study: Inappropriate Cancer Screenings Continue
Novartis Manufacturing Plant Closes After Drug Mix-ups
FDA Announces Classwide REMS for TIRF Medications
New Infants' Acetaminophen Products Hit Store Shelves
Avoid Environmental Factors Linked to Breast Cancer
Risk for Thrombosis Prompts REMS for Rivaroxaban
Common Drugs Implicated in Most Emergency Hospitalizations
CDC Launches Campaign for Child Medication Safety
HHS Blocks Expanded OTC Access to Plan B
Push Is On to Vaccinate Pregnant, Postpartum Women
FDA Committee Votes to Broaden PCV13 Indication
AAFP Foundation Program Aims to Fight Chronic Disease
NIAAA Alcohol Screening Guide Targets Teens
Walgreens, AAFP Launch Flu Vaccine Pilot in Five States
Helping Patients Quit Smoking Starts With a Question
Trilipix Efficacy in Question, Says FDA
USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening
AAFP Endorses ACP Guideline on ED
ACIP Recommends Expanded HPV, Hepatitis B Vaccination
Bacterial Contamination Spurs Nasal Spray Recall
CDC Renews Call for PCV13 Vaccination
USPSTF Recommends Against PSA Screening
AAFP Supports HHS' Million Hearts Initiative
FDA Phases Out Primatene Mist Inhalers
AHRQ Guides Explain Benefits, Risks of GERD Treatments
Office Champions Project Nets Smoking Cessation Gains
Multiple Lots of Oral Contraceptives Recalled
New Vaccine Review Finds Few Adverse Events
HPV Vaccination Rates Still Lag, Says CDC
Renal Injury Prompts Reclast Label Changes
High-dose Citalopram Linked to Abnormal Heart Rhythms
AHRQ Sleep Apnea Guides Review Diagnosis, Management
Board Chair Spotlights Breadth of Family Medicine Training
USPSTF Softens Stance on Bladder Cancer Screening
HHS Expands Coverage for Women's Preventive Services
Teledermatology Project Aids Underserved Patients
